Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
Open Access
- 20 July 2018
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 5 (9) , 1037-1047
Abstract
Objective: To study risk factors for decreasing aβ1–42 concentrations in cerebrospinal fluid (CSF) in cognitively unimpaired individuals with initially normal amyloid and tau markers, and to investigate whether such aβ1–42 decreases are associated with subsequent decline in cognition and other biomarkers of Alzheimer's disease.Methods: Cognitively normal subjects (n = 83, 75 ± 5 years, 35(42%) female) with normal CSF aβ1–42 and tau and repeated CSF sampling were selected from ADNI. Subject level slopes of aβ1–42 decreases were estimated with mixed models. We tested associations of baseline APP processing markers (BACE1 activity, aβ1–40, aβ1–38 and sAPPβ) and decreasing aβ1–42 levels by including an interaction term between time and APP marker. Associations between decreasing aβ1–42 levels and clinical decline (i.e., progression to mild cognitive impairment or dementia, MMSE, memory functioning) and biological decline (tau, hippocampal volume, glucose processing and amyloid PET) over a time period of 8–10 years were assessed.Results: Aβ1–42 levels decreased annually with −4.6 ± 1 pg/mL. Higher baseline BACE1 activity (β(se) = −0.06(0.03), P < 0.05), aβ1–40 (β(se)= −0.11(.03), P < 0.001), and aβ1–38 levels (β(se) = −0.11(0.03), P < 0.001) predicted faster decreasing aβ1–42. The fastest tertile of decreasing aβ1–42 rates was associated with subsequent pathophysiological processes: 11(14%) subjects developed abnormal amyloid levels after 3 ± 1.7 years, showed increased risk for clinical progression (Hazard Ratio[95CI] = 4.8[1.1–21.0]), decreases in MMSE, glucose metabolism and hippocampal volume, and increased CSF tau and amyloid aggregation on PET (all P < 0.05).Interpretation: Higher APP processing and fast decreasing aβ1–42 could be among the earliest, pre‐amyloid, pathological changes in Alzheimer's disease.Keywords
Funding Information
- ZonMw (73305056, 733050824)
- Alzheimer's Disease Neuroimaging Initiative
- National Institutes of Health (U01 AG024904)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Canadian Institutes of Health Research
This publication has 47 references indexed in Scilit:
- Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic ConsiderationsJournal of Nuclear Medicine, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- FreeSurferNeuroImage, 2012
- Bidirectional Relationship between Functional Connectivity and Amyloid-β Deposition in Mouse BrainJournal of Neuroscience, 2012
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 2011
- Neuronal activity regulates the regional vulnerability to amyloid-β depositionNature Neuroscience, 2011
- Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Alzheimer's Disease Is a Synaptic FailureScience, 2002
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992